


**Product Name** : Defactinib  
**Cat. No.** : PC-42951  
**CAS No.** : 1073154-85-4  
**Molecular Formula** : C<sub>20</sub>H<sub>21</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub>S  
**Molecular Weight** : 510.4927  
**Target** : Focal Adhesion Kinase (FAK)  
**Solubility** : DMSO: ≥ 39 mg/mL



## Biological Activity

Defactinib (VS-6063, PF-04554878) is a potent, selective and orally active **FAK** inhibitor, selectively inhibits pFAK (Tyr397) in a dose-dependent manner in cancer cell lines.

Defactinib shows no statistically significant changes in FAK phosphorylation at the other residues (Tyr 576/577, Tyr 925, or Tyr 861), also inhibits Pyk2 Tyr402 phosphorylation in HeyA8 cells.

Defactinib markedly decreases proliferation and increases apoptosis combined with paclitaxel, reduces levels of AKT and YB-1 in taxane-resistant cell lines.

Defactinib significantly reduces tumor growth, synergized with the mTOR inhibitor everolimus in xenograft models of pancreatic tumor.

## References

Kang Y, et al. *J Natl Cancer Inst.* 2013 Oct 2;105(19):1485-95.

Shimizu T, et al. *Cancer Chemother Pharmacol.* 2016 May;77(5):997-1003.

Jones SF, et al. *Invest New Drugs.* 2015 Oct;33(5):1100-7.

François RA, et al. *J Natl Cancer Inst.* 2015 May 12;107(8). pii: djv123.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com